Elizabeth L Donley from 9201 Bear Claw Way, Madison, WI 53717, age 61, Phone: 6088313592

Resumes

Chief Executive Officer

view source

Location:

504 south Rosa Rd, Madison, WI 53705

Industry:

Biotechnology

Work:

Ttoadvisors 2006 - 2008
Managing Director
Wisconsin Alumni Research Foundation Jul 1998 - Oct 2006
General Counsel and Director of Business Development
Stemina Biomarker Discovery Neuropointdx Jul 1998 - Oct 2006
Chief Executive Officer
Stemina Biomarker Discovery, Inc. Jul 1998 - Oct 2006
Chief Executive Officer
Quarles & Brady Llp Aug 1994 - Jul 1998
Associate

Education:

University of Wisconsin - Madison 2000 - 2004
Master of Science, Masters University of Wisconsin Law School 1991 - 1994
Doctor of Jurisprudence, Doctorates, Law University of Wisconsin - Whitewater 1989 - 1993
Master of Business Administration, Masters, Finance University of Wisconsin - Madison 1987
Edgewood High School
Miami University

Skills:

Licensing
Biotechnology
Intellectual Property
Life Sciences
Technology Transfer
Lifesciences
Commercialization
Pharmaceutical Industry
Start Ups
Drug Discovery
Protein Chemistry
Venture Capital
Genomics
Entrepreneurship
Biochemistry
Strategy
Patents
Biopharmaceuticals
Molecular Biology
Drug Development
Cell
Cancer
Clinical Trials
Cro
Bioinformatics
R&D
Glp
Cell Culture
Immunology
Chemistry
Clinical Development
Validation
Medical Devices
Science
Infectious Diseases
Fda
Vaccines
Oncology
Analytical Chemistry
Regulatory Affairs
Hplc
Cell Biology
Strategic Planning
Management
Leadership
Business Development
Research
Business Strategy
Research and Development

Elizabeth Donley

view source

Elizabeth Donley

view source

Owner, Stemina Biomarker Discovery

view source

Position:

CEO at Stemina Biomarker Discovery

Location:

Madison, Wisconsin Area

Industry:

Biotechnology

Work:

Stemina Biomarker Discovery since Oct 2006
CEO
TTOAdvisors 2006 - 2008
Managing Director
Wisconsin Alumni Research Foundation Jul 1998 - Oct 2006
General Counsel and Director of Business Development
US Bank 1988 - 1992
Commercial Lender

Education:

University of Wisconsin-Madison 2000 - 2004
MS, Bacteriology University of Wisconsin Law School 1991 - 1994
JD, Law University of Wisconsin-Whitewater 1989 - 1993
MBA, Finance Miami University

Skills:

Licensing
Biotechnology
Intellectual Property
Life Sciences
Technology Transfer
Lifesciences
Commercialization

Lawyers & Attorneys

Elizabeth L R Donley, Madison WI - Lawyer

view source

Address:

Stemina Biomarker Discovery Inc
504 S Rosa Rd 150, Madison, WI 53719
6082040104 (Office)

Licenses:

Wisconsin - Good Standing 1994

Education:

University of Wisconsin Law School
Graduated - 1994

Languages:

English

Elizabeth Donley - Lawyer

view source

ISLN:

918242295

Admitted:

2003

Law School:

University of Maryland School of Law, 1990

Elizabeth L R Donley, Madison WI - Lawyer

view source

Address:

9201 Bear Claw Way, Madison, WI 53717

Phone:

6085779209 (Phone)

Jurisdiction:

Wisconsin

Education:

U of Wisconsin

Memberships:

Wisconsin State Bar

License Records

Elizabeth Anne Donley

License #:

29274 - Active

Issued Date:

May 13, 2011

Renew Date:

Dec 1, 2015

Expiration Date:

Nov 30, 2017

Type:

Certified Public Accountant

Us Patents

Predicting Human Developmental Toxicity Of Pharmaceuticals Using Human Stem-Like Cells And Metabolomics
view source
US Patent:

20110312019, Dec 22, 2011
Filed:

Mar 22, 2011
Appl. No.:

13/069326
Inventors:

Paul R. WEST - Arena WI, US
Alan M. SMITH - Madison WI, US
Elizabeth L.R. DONLEY - Madison WI, US
Gabriela G. CEZAR - Madison WI, US
Assignee:

Stemina Biomarker Discovery, Inc. - Madison WI
International Classification:

C12Q 1/18
US Classification:

435 32
Abstract:

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Diagnosis And Treatment Of Autism Spectrum Disorders Based On Amine Containing Metabotypes
view source
US Patent:

20200348319, Nov 5, 2020
Filed:

Jan 29, 2019
Appl. No.:

16/961995
Inventors:

- Madison WI, US
Joseph King - Madison WI, US
Paul R. West - Arena WI, US
Michael Ludwig - Middleton WI, US
Elizabeth L.R. Donley - Madison WI, US
Robert Burrier - Verona WI, US
International Classification:

G01N 33/68
Abstract:

The invention provides methods of diagnosing autism spectrum disorders (ASD) by analyzing ratios of concentrations of selected amine containing compounds in a sample, such as a blood sample, from a subject. Based on the discovery that specific amine containing compounds and their ratios are dysregulated in patients with ASD, these metabotypes or subtypes of metabolism have the potential to diagnose earlier and suggest more precise treatment based on the metabolism of the individual. The invention provides methods of analyzing amine containing compounds and ratios in a test subject and determining whether the test subject has or is at risk of developing an ASD by comparing ratios from the test subject to ratios from subjects diagnosed with a neurodevelopmental disorder such as ASD who share a common profile of metabolism which is not found in the majority of typically developing subjects. The invention also provides methods of determining a course of treatment for an individual that has or is at risk of developing an ASD based on the individuals metabotype.

Autism Subsets
view source
US Patent:

20190178900, Jun 13, 2019
Filed:

May 12, 2017
Appl. No.:

16/301044
Inventors:

Paul West - Arena WI, US
Robert Burrier - Verona WI, US
Joseph King - Madison WI, US
Roxana Alexandridis - Madison WI, US
Laura Egnash - Deforest WI, US
Elizabeth L.R. Donley - Madison WI, US
Michael Ludwig - Middleton WI, US
Assignee:

Stemina Biomarker Discovery, Inc. - Madison WI
International Classification:

G01N 33/68
G01N 30/72
Abstract:

With the present invention, metabolomics biomarkers are used to identify subtypes within the autism spectrum disorder (ASD) population. In one embodiment, levels of the metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) of about six times or greater than the median level in typically developing (TD) individuals or about 2 μM or greater place the individual in an autism subpopulation that includes less than 20% of the total ASD population. Thus, CMPF is a biomarker able to discriminate a subtype of ASD.

Predicting Human Developmental Toxicity Of Pharmaceuticals Using Human Stem-Like Cells And Metabolomics
view source
US Patent:

20140273069, Sep 18, 2014
Filed:

Apr 21, 2014
Appl. No.:

14/257299
Inventors:

- Madison WI, US
Alan M. Smith - Madison WI, US
Elizabeth L.R. Donley - Madison WI, US
Gabriela G. Cezar - Madison WI, US
Assignee:

STEMINA BIOMARKER DISCOVERY, INC. - Madison WI
International Classification:

G01N 33/50
US Classification:

435 29
Abstract:

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.